The Pharmaceutical Education & Research Center (PERC) at Campbell University offers analytical, formulation, R&D and training services to the pharma and biotech industries, compounding pharmacies, government agencies and other academic institutions.

Ardeal Research Institute is a non-profit organization that develops drug discovery capabilities of the natural resources in Western North Carolina. The Institute has collaboration agreements in place with Brevard College and the N.C. Arboretum.

Avior Bio is an developing a nanoparticle-based drug delivery technology to deliver lipophilic drugs with high bioavailability. It is testing its technology using a molecule for the treatment of pruritus in chronic kidney disease.

BioAgilytix is a bioanalytical lab specializing in large-molecule bioanalysis, offering PK, immunogenicity, biomarkers and cell-based assays in support of the development and release testing of biologics and small-molecule therapeutics.

Biogen discovers, develops and manufactures therapies for serious neurological diseases. This site houses oral solid dose and anti-sense oligonucleotide production, packaging and fill/finish operations, as well as a Global Business Services center.

BioKier develops proprietary adjuvant treatments for diabetes and related disorders. BioKier has identified a therapeutic opportunity based on gastric bypass surgery and is developing a novel treatment for diabetes.

DMK Pharmaceuticals develops small-molecule analgesics that have reduced side effects, such as abuse potential, respiratory depression, nausea, vomiting and itching, that are currently associated with marketed analgesics.

Emergo Therapeutics develops drugs to reduce the production of inflammatory cytokines from mast cells and improve the functioning of the immune system in various potential indications, starting with infectious diseases.

EncepHeal Therapeutics develops neurotherapeutics to treat substance abuse and mental health disorders through working partnerships with academic institutions, private companies and foundations and government agencies.

Exodos Life Sciences advances product concepts through the 505(b)(2) process to early clinical proof-of-principle and sale. Exodus specializes in topical formulations for the treatment of pain and inflammation, cold sores and nail fungis.

FHI 360 is a nonprofit human development organization that focuses on family planning, reproductive health and HIV/AIDs by advancing locally-driven solutions. The laboratory in Durham offers medical device and pharmaceutical testing services.

FibroStatin develops treatments for drug resistant cancer and organ fibrosis using its proprietary GPBP technology that has identified a novel and preferred pathway for inhibiting the cell epithelial-to-mesenchymal transition (EMT).

Fujifilm Diosynth Biotechnologies provides biologics contract development and manufacturing. Services include cell line development, process and analytical development, clinical and commercial manufacturing and bioprocess research and development.

Glenmark Pharmaceuticals discovers small-molecule drugs and biologics in the areas of oncology, respiratory disease and dermatology, and manufactures and distributes APIs and generics. The Monroe site manufactures oral solids, injectables and topicals.

GlaxoSmithKline manufactures solid-dose products, including tablets and capsules, at its Zebulon facility. The plant also does granulation, drying and packaging, and contract manufacturing of antibiotics for other companies.

Hammock Pharmaceuticals licenses and develops women's health and urology products. It is developing a metronidazole and clindamycin vaginal gel for the treatment of bacterial vaginosis, and a urology product for the treatment of radiation cystitis.

Invitrox provides GLP-compliant bioanalytical services for nonclinical and clinical drug development studies, with expertise in method development and validation, small and large molecules, sample analysis, metabolites, biomarkers and drug monitoring.

Irex Pharma develops therapies to control life-threatening excess mucus in pulmonary patients. Irex utilizes a novel panel of assays to discover and optimize small molecule inhibitors of a new target required for mucus overproduction.

Karamedica has developed a plasma treatment system to decontaminate chitosan, a biopolymer found in the shells of shrimps and crabs. Karamdica is currently developing a nanoparticle therapy for cerebral amyloid angiopathy.

Kowa Research Institute, a division of Kowa Company Ltd., develops therapeutic drugs for the treatment of cardio-metabolic diseases such as diabetes and atherosclerosis, pain and sensory organ disorders.

Contact us

Life Science Intelligence at NCBiotech strives to provide accurate and current data on the bioscience community in North Carolina. You may reproduce the NCBiotech Company Directory site content for any legal purpose with proper attribution. Attribution shall take the following form: "Data provided by the North Carolina Biotechnology Center, www.ncbiotech.org."